Remove .Net Remove 2019 Remove Develop Remove Report
article thumbnail

Veritone Picks Up $6.5M In PPP Loans

socalTECH

Costa Mesa-based artificial intelligence software developer Veritone --which is publicly traded on the NASDAQ as VERI--reported that it has received a total of $6.5M Veritone has over 300 employees and had 2019 net revenues of $49.6M. in loans under the Paycheck Protection Program (PPP).

article thumbnail

Viant Files For IPO

socalTECH

Irvine-based Viant Technology, a developer of advertising software, has filed for an IPO, saying in a filing with the SEC that it is looking to raise up to $150M in an IPO on the Nasdaq Global Market as DSP. The company reported $9.9M in net income on $164M in revenues for the year ended December 31, 2019.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Activision Blizzard To Slash Almost 800 Employees

socalTECH

Santa Monica-based game developer Activision Blizzard says it is slashing 8 percent of its staff, or nearly 800 employees, as a part of a restructuring effort at the company. The move comes even as Activions Blizzard reported record net revenues in 2018 of $7.50 bllion, up from the $7.02 billion it had in revenues for 2017.

article thumbnail

The Five Major Tech Trends of 2016

Xconomy

Back in 2013, Google reported that 90 percent of multiple device owners switch between screens to complete tasks, using an average of three different combinations every day. Meanwhile, biometrics has stepped out of the realm of sci-fi and into the mainstream, playing an important role in the fight against cybercrime. billion.

article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. —South San Francisco, CA-based Denali Therapeutics, with ambitions to develop drugs for several neurodegenerative diseases, bagged $130 million in a Series B and unveiled a series of deals.

Pricing 40